# An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

> **NCT02211014** · PHASE1 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 27 (actual)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **DRUG:** acalabrutinib

## Key facts

- **NCT ID:** NCT02211014
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2019-04-26
- **Final completion:** 2019-04-26
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211014, "An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02211014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*